1200397-23-4

Basic information

• Product Name: 2-(3-(2,6-dimethylbenzyloxy)phenyl)-2-methylpropanoic acid
• Synonyms: 2-(3-(2,6-dimethylbenzyloxy)phenyl)-2-methylpropanoic acid
• CAS NO: 1200397-23-4
• Molecular Weight: 298.382
• Mol File: 1200397-23-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-(3-(2,6-dimethylbenzyloxy)phenyl)-2-methylpropanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-(2,6-dimethylbenzyloxy)phenyl)-2-methylpropanoic acid(1200397-23-4)
• EPA Substance Registry System: 2-(3-(2,6-dimethylbenzyloxy)phenyl)-2-methylpropanoic acid(1200397-23-4)

Safety Data

• Hazardous Substances Data: 1200397-23-4(Hazardous Substances Data)

Upstream product

• 71060-40-7 2-(3-hydroxyphenyl)-2-methylpropanenitrile 
• 17653-93-9 2-(3'-Methoxyphenyl)-2-methylpropionitrile 
• 1200397-41-6 2-(3-(2,6-dimethylbenzyloxy)phenyl)-2-methylpropanenitrile 
• 1200397-42-7 2-(3-(2,6-dimethylbenzyloxy)phenyl)-2-methylpropanal 

Relevant articles and documents

COMPOUNDS AND METHOD FOR REDUCING URIC ACID

Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula (I) or a pharmaceutically acceptable salt thereof. In Formula (I) m is 0, 1, 2, 3 or 4; n is 0 or 1; m + n is not more than 4; t is 0 or 1; q is 0 or 1; and r is 0, 1 or 2. R6 is hydrogen, methyl or ethyl and R12 is hydrogen or methyl, or R6 is hydroxy and R12 is hydrogen, or R6 is O and R12 is absent, or R6 and R12 together are -CH2CH2-. R7 is hydrogen or alkyl having from 1 to 3 carbon atoms. One of R8 and R9 is alkyl having from 1 to 3 carbon atoms, and the other is hydrogen or alkyl having from 1 to 3 carbon atoms. R10 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms or alkoxy having from 1 to 3 carbon atoms. X is C(O) and r is 0 and t is 0; or X is NH(R11) wherein R11 is hydrogen or alkyl having from 1 to 3 carbon atoms. A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from halo, hydroxy, methyl, ethyl, perfluoromethyl, methoxy, ethoxy, and perfluoromethoxy; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of Formula (I) by a ring carbon; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently monosubstituted by methyl or ethyl. The uric acid-lowering effects of the Compounds of Formula (I) are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, and cognitive impairment.